Evidence map›Paper›PMID 40620464›Full record

ArticleDrug design, development and therapy2025

Bibliometric and Visualized Analysis of Artemisinin and Its Derivatives in Cancer.

Jiaming Feng, Yuqing He, Ting Bai, Qianhui You, Huici Zhu, Chengyao Jia, Baonian Liu, Shaoling Li

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaming Feng *Department of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID 0009-0002-7748-5571
Yuqing He *Department of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Ting Bai *Department of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Qianhui You *Department of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Huici ZhuDepartment of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Chengyao JiaGuanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China.
Baonian LiuDepartment of Anatomy, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Shaoling LiDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Artemisinin, found in the traditional Chinese medicine (TCM) Aim of the Study: We conducted this bibliometric study with the aim of providing researchers in the field with an all-around summary of artemisinin and its derivatives in cancer, visualizing current research advances, identifying hotspots, and ultimately outlining cutting-edge trends for future development. Methods: A total of 927 relevant publications from 1990 to 2023 were accessed from the WOSCC database and analyzed bibliometrically utilizing software including CiteSpace VOSviewer and Microsoft Excel. Results: Global publications in artemisinin and tumor therapy have steadily increased. China is considered the leading country in terms of publication numbers, and Chinese scholars have been influential in the field of artemisinin and its derivatives in the prevention and treatment of cancer. Cluster analysis of co-cited references depicted artemisinin-type drugs, bax-mediated intrinsic pathways, and infected erythrocytes as the most noteworthy topics. In contrast, the keywords analysis revealed a strong emphasis on the issues of cancer, in-vitro, cycle arrest, anticancer activity, and plasmodium-falciparum. Conclusion: This study provides a comprehensive overview of relevant research trends by explicitly analyzing the published literature associated with artemisinin and its derivatives in cancer. The results of this multifaceted analysis can provide valuable data that offers ample insights for the field and for researchers wishing to venture into the field.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicArtemisininsBibliometricsNeoplasmsArtemisia annuaHumansMedicine, Chinese TraditionalAntineoplastic AgentsAntineoplastic Agents, PhytogenicartemisininArtemisininsartemisininbibliometric analysiscancertherapeutic agenttraditional Chinese medicine

Identifiers

PMID40620464
PMCPMC12227322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.